个人资料
教育经历教育经历: 2012/9-2015/7,中国科学院上海药物研究所,药物设计 2010/9-2012/7,中国科学院上海药物研究所,药物设计 2006/9-2010/7,郑州大学,化学,学士 工作经历科研与学术工作经历: 2022/5-至今,华东师范大学,生命科学学院,青年研究员 2016/12-2022/5,华东师范大学,生命科学学院,专职副研究员 2015/8-2016/11,中国科学院过程工程研究所,离子液体与绿色工程研究部,助理研究员 个人简介张乾森,华东师范大学生命科学学院,青年研究员,博士生导师,华东师范大学紫江青年学者。主要研究方向为:利用人工智能、计算生物学等手段探究重大疾病相关药物靶标调控机制和分子设计研究。近年来,以第一和通讯作者(含共同)在Nature Chemical Biology、PNAS (2篇)、Cell Research (2篇,其中1篇封面论文)、Cell Reports、J Med Chem、CCS Chemistry和J Mol Cell Biol (封面论文)等期刊发表论文19篇。申请发明专利9项,授权4项。主持国家自然科学基金2项,上海市扬帆计划项目,并以项目骨干身份参与国家重大专项和重点研发计划项目2项。 社会兼职研究方向1)人工智能技术驱动的蛋白质动态构象研究; 2)计算机辅助药物设计。 招生与培养开授课程科研项目1. 国家自然科学基金面上项目,82273857,靶向中枢Hv1通道抑制剂发现及其治疗帕金森疾病功能研究;2023/01-2026/12,在研,主持,52万元。 2. 国家科技重大专项项目,新靶点小分子药物新品种研发及其关键创新技术体系;任务层项目,2018ZX09711002-002-004、离子通道变构动态构象技术,2018/1-2020/12,结题,任务层项目负责人,个人被支持302.65万。 3. 国家自然科学基金青年科学基金项目,31800699、PIP2对KCNQ通道各亚型不同激活能力的分子机制研究,2019/01-2021/12,结题,结题,25万元。 4.国家重点研发计划,2018YFA0508100,基于 GPCR 和离子通道结构的动态调控机制研究与变构调控分子发现、2018/5/1-2023/4/30,结题,骨干。个人被支持93万元。 5.上海市青年科技英才扬帆计划,18YF1406600,Retigabine选择性激活KCNQ离子通道亚型机制的分子动力学模拟和实验研究、2018/5/01-2021/4/30,结题,主持,20万元。 学术成果代表性研究成果 2024年 (1) Shaoying Zhang#, Demin Ma# , Kun Wang# , Ya Li#, Zhenni Yang, Xiaoxiao Li, Junnan Li, Jiangnan He, Lianghe Mei, Yangliang Ye, Zongsheng Chen, Juwen Shen, Panpan Hou, Jiangtao Guo*, Qiansen Zhang*, Huaiyu Yang*. A small-molecule activation mechanism that directly opens the KCNQ2 channel. Nature Chemical Biology. 2024 Jan 2. doi: 10.1038/s41589-023-01515-y.(共同通讯)(IF=14.86)
(2) Yuan Weng#, Xinyu Yang#, Qiansen Zhang#,*, Ying Chen, Yueming Xu, Chenyu Zhu, Qiong Xie, Yonghui Wang, Huaiyu Yang, Mingyao Liu, Weiqiang Lu* & Gaojie Song*. Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A2 receptors. Science China Life Sciences. 2024 Jan 31. doi: 10.1007/s11427-023-2459-8. (共同通讯和共一作者)(IF=9.1)
2023年 Heng Liu#, Maya M. Polovitskaya#, Linlin Yang*, Meiling Li, Hongyue Li, Zhen Han, Jianguo Wu, Qiansen Zhang*, Thomas J. Jentsch*, and Jun Liao*. Structural insights into anion selectivity and activation mechanism of LRRC8 volume-regulated anion channels. Cell Reports. 2023, 42.8. (共同通讯)(IF=9.9)
2022年 (1) Qiansen Zhang#, Yimin Ren#,Yiqing Mo#, Peipei Guo#, Ping Liao#, Yuncheng Luo#, Jie Mu, Zhuo Chen, Yang Zhang, Ya Li, Linghui Yang, Daqing Liao, Jie Fu, Juwen Shen, Wei Huang, Xuewen Xu, Yanyan Guo, Lianghe Mei, Yunxia Zuo, Jin Liu, Huaiyu Yang*, Ruotian Jiang*. Inhibiting Hv1 channel in peripheral sensory neurons attenuates chronic inflammatory pain and opioid side effects. Cell Research. 2022, 32, 461–476. (封面论文+Research highlight报道)(IF=46.3)
(2) Huang Chen#, Wenbo Zhou#, Aiwu Bian#, Qiansen Zhang#, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, Jianghua Zheng, Yihua Chen*, Mingyao Liu*, Zhengfang Yi*. Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer. Clinical Cancer Research. 2022, CCR-22-0997. (共同第一作者)(IF=11.5)
(3) Qiansen Zhang#, Jie Fu#, Shaoying Zhang, Peipei Guo, Shijie Liu, Juwen Shen, Jiangtao Guo, Huaiyu Yang*. ‘C-type’ closed state and gating mechanisms of K2P channels revealed by conformational changes of the TREK-1 channel. Journal of Molecular Cell Biology. 2022, https://doi.org/10.1093/jmcb/mjac002. (封面论文+Research highlight报道)(IF=8.18)
2021年 (1) Xiaoxiao Li#, Qiansen Zhang#, Peipei Guo#, Jie Fu, Lianghe Mei, Dashuai Lv, Jiangqin Wang, Dongwu Lai, Sheng Ye, Huaiyu Yang*, Jiangtao Guo*. Molecular basis for ligand activation of the human KCNQ2 channel. Cell Research. 2021, 31: 52-61. (共同第一作者)(IF=46.3)
(2) Bei-Er Jiang#, Xingwu Jiang#, Qiansen Zhang#, Qiuwen Liang, Zi-Liang Qiu, Xiang-Bai Sun, Jun-Jie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Li-Fang Yu*, Weiqiang Lu*, and Han-Kun Zhang*. From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis. J. Med. Chem. 2021, 64: 385–403. (共同第一作者)(IF=8.0)
2020年以前 (1) Qiansen Zhang#, Pingzheng Zhou#, Zhuxi Chen, Min Li, Hualiang Jiang, ZhaobingGao*, and Huaiyu Yang*. Dynamic PIP2 interactions with voltage sensor elements contribute to KCNQ2 channel gating. Proc Natl Acad Sci U S A. 2013, 110(50):20093-8.(IF=12.8)
(2) Huiying Li#, Qiansen Zhang#, Yiran Gu#, Yingyin Wu, Yamei Wang, Liren Wang, Shijie Feng, Yaqiang Hu, Yansen Zheng, Yongmei Li, Haifeng Ye, Bin Zhou, Longnian Lin, Mingyao Liu*, Huaiyu Yang*, and Dali Li*. Efficient photoactivatable Dre recombinase for cell type-specific spatiotemporal control of genome engineering in the mouse. Proc Natl Acad Sci U S A. 2020, 117 (52): 33426-33435.(共同第一作者)(IF=12.8)
(3) Wang, M.#, Zhang, Q. S.#, Jian, H., Liu, S., Li, J., Wang, A., . . . Bai, S. Role of Thermolysin in Catalytic-Controlled Self-Assembly of Fmoc-Dipeptides. CCS Chemistry. 2020,2, 317–328 (共同第一作者)(IF=11.2)
(4) Ruoyu Wang#, Qiansen Zhang#, Yi Zhang, Hanchang Shi, Kim Truc Nguyen, and Xiaohong Zhou*. Unconventional Split Aptamers Cleaved at Functionally Essential Sites Preserve Biorecognition Capability. Analytical Chemistry, 2019, 91(24), 15811-15817. (共同第一作者) (IF=8.0) 专利申请和授权 (1) 阳怀宇; 蒋若天; 张乾森; 预防和治疗慢性疼痛的化合物及其应用, 2018-11-26, 中国, ZL201811218997.2 (专利授权) (2) 陈益华; 刘明耀; 郭伟凯; 邢雅婧; 黄懂霞; 易正芳; 杜冰; 张乾森; 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用, 2017-5-31, 中国, ZL201710405225.9 (专利授权) (3) 阳怀宇; 李扬; 郭飞; 蒋华良; 张乾森; 作为防治精神障碍疾病的苯胺类化合物, 2018-9-06, 中国, 201811038093 .1 (专利申请) (4) 黄蔚; 蒋华良; 阳怀宇; 周芒; 仇运广; 王志杰; 张乾森; 一类吲哚酮类化合物、其制备方法、药物组合物和用途, 2018-8-13, 中国, CN201810917018.6 (专利申请) (5) 阳怀宇; 蒋若天; 张乾森; 预防和治疗慢性疼痛药物的胍类化合物, 2019-12-11, 中国, CN201911266613.9 (专利申请) 荣誉及奖励 |